GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (STU:47M) » Definitions » EV-to-FCF

MedMira (STU:47M) EV-to-FCF : -33.36 (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is MedMira EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, MedMira's Enterprise Value is €45.70 Mil. MedMira's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 was €-1.37 Mil. Therefore, MedMira's EV-to-FCF for today is -33.36.

The historical rank and industry rank for MedMira's EV-to-FCF or its related term are showing as below:

STU:47M' s EV-to-FCF Range Over the Past 10 Years
Min: -914.36   Med: -10.79   Max: 2745.44
Current: -37.35

During the past 13 years, the highest EV-to-FCF of MedMira was 2745.44. The lowest was -914.36. And the median was -10.79.

STU:47M's EV-to-FCF is ranked worse than
100% of 367 companies
in the Biotechnology industry
Industry Median: 9.77 vs STU:47M: -37.35

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-24), MedMira's stock price is €0.052. MedMira's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was €-0.004. Therefore, MedMira's PE Ratio for today is At Loss.


MedMira EV-to-FCF Historical Data

The historical data trend for MedMira's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira EV-to-FCF Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.05 -911.46 -167.71 -48.85 -54.01

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -120.06 -91.27 -54.01 -42.13 -35.60

Competitive Comparison of MedMira's EV-to-FCF

For the Biotechnology subindustry, MedMira's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where MedMira's EV-to-FCF falls into.



MedMira EV-to-FCF Calculation

MedMira's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=45.697/-1.37
=-33.36

MedMira's current Enterprise Value is €45.70 Mil.
MedMira's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.37 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira  (STU:47M) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

MedMira's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.052/-0.004
=At Loss

MedMira's share price for today is €0.052.
MedMira's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.004.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


MedMira EV-to-FCF Related Terms

Thank you for viewing the detailed overview of MedMira's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (STU:47M) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (STU:47M) Headlines

No Headlines